A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke | Zendy

Philip Teal | Zendy; Stephen M. Davis | Zendy; Werner Hacke | Zendy; Markku Kaste | Zendy; Patrick D. Lyden | Zendy; Monika Fierus | Zendy

Open Access

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke

Author(s) -

Philip Teal,

Stephen M. Davis,

Werner Hacke,

Markku Kaste,

Patrick D. Lyden,

Monika Fierus

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.551382

Subject(s) - medicine , tolerability , placebo , anesthesia , randomized controlled trial , clinical endpoint , stroke (engine) , clinical trial , pharmacodynamics , population , vital signs , adverse effect , pharmacokinetics , mechanical engineering , alternative medicine , environmental health , pathology , engineering

Repinotan hydrochloride is a serotonin (5-HT)(1A) receptor full agonist with evidence of neuroprotection in animal models of permanent and transient focal ischemia. The purpose of this Phase IIb study was to investigate the efficacy, safety, and tolerability of a targeted exposure to repinotan in patients with acute ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research